This article will be permanently flagged as inappropriate and made unaccessible to everyone. Are you certain this article is inappropriate? Excessive Violence Sexual Content Political / Social
Email Address:
Article Id: WHEBN0020699915 Reproduction Date:
Relcovaptan (SR-49059) is a non-peptide vasopressin receptor antagonist, selective for the V1a subtype.[1] It has shown positive initial results in tests against Raynaud's disease, dysmenorrhoea, and tocolysis,[2] although it is not yet approved for clinical use.
M: END
anat/phys/devp/horm
noco (d)/cong/tumr, sysi/epon
proc, drug (A10/H1/H2/H3/H5)
Arginine vasopressin receptor 2, Vasopressin, Arginine vasopressin receptor 1B, Oxytocin receptor, Open access
Tolvaptan, Conivaptan, Lixivaptan, Relcovaptan, Demeclocycline, Arginine vasopressin receptor 1A